Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The response’s stated safety categories (serious infections, mortality, malignancy, MACE, thrombosis) are directly supported by OPZELURA FDA label Sections 5.1–5.5, with no contradictions identified relative to the provided label excerpts.
Category Scores
Accurate Statements
Serious infections risk for OPZELURA (including serious and sometimes fatal infections; guidance to avoid in active serious infection and interrupt/discontinue for serious infection/opportunistic infection/sepsis).
Supported by SECTION 5.1 (Serious Infections).
Increased mortality risk for OPZELURA (higher rate of all-cause mortality including sudden cardiovascular death observed in RA postmarketing safety study vs TNF blockers).
Supported by SECTION 5.2 (Mortality).
Malignancy risk for OPZELURA (malignancies including lymphomas observed with oral JAK inhibitors; higher rate of malignancies vs TNF blockers; periodic skin examinations guidance).
Supported by SECTION 5.3 (Malignancy and Lymphoproliferative Disorders).
MACE risk for OPZELURA (higher rate of MACE vs TNF blockers; discontinue in patients with MI or stroke).
Supported by SECTION 5.4 (Major Adverse Cardiovascular Events (MACE)).
Thrombosis risk for OPZELURA (thromboembolic events including DVT, PE, arterial thrombosis; some resulted in death; avoid in higher-risk patients; discontinue and evaluate/treat if symptoms occur).
Supported by SECTION 5.5 (Thrombosis).
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The evaluated response only asserts label-supported safety risks and does not introduce incorrect or conflicting safety information relative to the provided OPZELURA label excerpts.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement